WVU awarded grant to study Alzheimer’s link to stress

Monongalia
WVU School of Medicine researcher Paul Chantler (rear) is studying the link between chronic stress and Alzheimer’s disease. By learning more about how a certain enzyme contributes to Alzheimer’s progression, he and his team can uncover new possibilities for slowing the disease’s progression or onset.

WVU School of Medicine researcher Paul Chantler (rear) is studying the link between chronic stress and Alzheimer’s disease. By learning more about how a certain enzyme contributes to Alzheimer’s progression, he and his team can uncover new possibilities for slowing the disease’s progression or onset. (WVU Photo/Aira Burkhart)

MORGANTOWN, W.Va. – One in nine Americans age 65 or older has Alzheimer’s disease, according to the Alzheimer’s Association. That’s about 6.2 million people, and if current trends continue, that number will likely swell to 12.7 million by 2050.

Paul Chantler—a researcher with the West Virginia University School of Medicine—is working to change those trends by investigating the link between chronic stress and Alzheimer’s disease. In particular, they’re using animal models to explore how naturally-occurring enzyme, xanthine oxidase, may sabotage the brain’s blood vessels in Alzheimer’s patients. 

The National Institutes of Health awarded WVU $2 million for the effort.

“Billions of dollars have been spent looking specifically at how amyloid tangles, tau and plaque processes in the brain contribute to dementia,” said Chantler, an associate professor in the Department of Exercise Physiology and the Department of Neuroscience. “The research has done really well in animal models, but when it made it to clinical trials, it’s fallen flat on its feet. So, NIH wanted to prioritize examining the vascular contributions to dementia. That’s where my research fits in well.”

He and his team will identify the effects that chronic psychological stress has on the disease’s progression, and they’ll use medication to block the problematic pathway and see whether doing so keeps the brain’s vasculature healthy.

What they learn could suggest new therapies for preserving the memory and cognition of Alzheimer’s patients and people at risk of developing the disease.

“If you know stress is a risk factor for dementia, then obviously you try and alleviate that stress,” Chantler said. “But, also, the drugs we’re using to block xanthine oxidase currently seem to prevent the vascular dysfunction that we see with dementia. Now, we’re currently looking at whether that leads to cognitive improvements, but it’s really exciting to say, ‘Well, even if you have a family history for dementia, maybe there are drugs out there that can diminish or delay some of the pathologies.’”

For WVUToday’s full report, click here.

Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, under Award Number R01NS117754. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.

Copyright 2022 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Link to 12 things you need to know page

WBOY 12 News Facebook Page

Trending Stories